« Previous
Next »
Titles
- Tezepelumab for severe asthma: final report2
- AMX0035 and oral edaravone for amyotrophic lateral sclerosis: final evidence report1
- Aducanumab for Alzheimer’s disease: effectiveness and value1
- Alirocumab for treatment of high cholesterol: effectiveness and value : new evidence update1
- Betibeglogene autotemcel for beta thalassemia: effectiveness and value : final evidence report1
- Crizanlizumab, voxelotor, and L-glutamine for sickle cell disease: effectiveness and value1
- Eculizumab and efgartigimod for the treatment of myasthenia gravis: effectiveness and value : final report1
- Fezolinetant for moderate to severe vasomotor symptoms associated with menopause: effectiveness and value : final evidence report1
- Gene therapies for sickle cell disease: final evidence report1
- Gene therapy for hemophilia B and an update on gene therapy for hemophilia A: effectiveness and value : final evidence report1
- JAK inhibitors and monoclonal antibodies for the treatment of atopic dermatitis: effectiveness and value : final evidence report1
- Mavacamten for hypertrophic cardiomyopathy: effectiveness and value : final evidence report and meeting summary1
- Medications for obesity management: effectiveness and value : final evidence report1
- Modulator treatments for cystic fibrosis: effectiveness and value1
- Nadofaragene firadenovec and oportuzumab monatox for BCG-unresponsive, non-muscle invasive bladder cancer: effectiveness and value : final report1
- Resmetirom and obeticholic acid for non-alcoholic steatohepatitis (NASH): final evidence report1
- Supervised injection facilities and other supervised consumption sites: effectiveness and value : final report1
- Treatments for anemia in chronic kidney disease: effectiveness and value : final evidence report1
- Unsupported price increase report: 2020 assessment1
- Valoctocogene roxaparvovec and emicizumab for hemophilia A without inhibitors: effectiveness and value : final report1